Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner. Targeting vimentin and/or the long noncoding RNA (lncRNA) ‘XIST’ could be an effective therapeutic strategy for treating aggressive breast cancer.
Tag: Protein Structure and Function
[ASAP] Helix-Guarded Molecular Clips for Cell-Free DNA Scavenging and Treatment of Systemic Lupus Erythematosus
Seesaw protein: Design of a protein that adopts interconvertible alternative functional conformations and its dynamics
Insights From Protein Frustration Analysis of BRD4-Cereblon Degrader Ternary Complexes Show Separation of Strong from Weak Degraders
PROteolysis TArgeting Chimeras (PROTACs), also known as Ligand-Directed Degraders (LDDs), are an innovative class of small molecules that leverage the ubiquitin-proteasome system to induce the degradation of target proteins. Structure based design methods are not readily applicable for designing LDDs due to the dynamic nature of the ternary complexes. This study investigates the dynamic properties… Continue reading Insights From Protein Frustration Analysis of BRD4-Cereblon Degrader Ternary Complexes Show Separation of Strong from Weak Degraders
[ASAP] A Nurr1 Agonist Derived from the Natural Ligand DHI Induces Neuroprotective Gene Expression
[ASAP] Small Ligand-Involved Pickering Droplet Interface Controls Reaction Selectivity of Metal Catalysts
G-quadruplexes catalyze protein folding by reshaping the energetic landscape
[ASAP] Ligand-Governed Regio- and Enantioselective [2 + 2 + 2] Cycloaddition of 1,7-Enynes: Assembly of the Benzo[c]chromen-1-ol Backbone and Access to Enantioenriched Cannabinol Bioisostere
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1>=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse. Methods This study assessed 5-year outcomes of first-line pembrolizumab monotherapy in a large, multicenter, real-world cohort of patients with advanced NSCLC… Continue reading Determinants of 5-year survival in patients with advanced NSCLC with PD-L1>=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry